A Study Of Varenicline For Smoking Cessation In Pancreatitis

Overview

About this study

The purpose of this study is to evaluate the efficacy of varenicline in helping patients with pancreatitis who smoke cigarettes achieve smoking cessation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for the duration of the study

  • Male or female, aged 18 or older

  • Diagnosed with either acute pancreatitis, recurrent acute pancreatitis or chronic pancreatitis as defined by the American Pancreatic Association

  • Currently smoking at least once a week.

  • Explicitly express a desire to quit within 30 days

  • Ability to take oral medication and be willing to adhere to the study intervention regimen

  • Willing and able to comply with trial protocol and follow-up

Exclusion Criteria:

  • Age < 18 years

  • No desire to quit smoking

  • Known allergic reactions to varenicline

  • History of seizures

  • Closed head trauma with any loss of consciousness or amnesia in the last 5 year

  • Ever history of closed head trauma with > 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma/brain contusion

  • History of chronic kidney disease (creatine clearance < 30 mL/minute)

  • History of bipolar disorder or psychosis

  • Unable to provide consent for self

  • Incarcerated

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/06/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Samuel Han, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions